The Cancer Genomics Shared Resource (CGSR) of the Wake Forest Baptist Comprehensive Cancer Center is a National Cancer Institute (NCI)-supported laboratory that provides comprehensive genomic, transcriptomic and epigenomic profiling analyses for research and diagnostic purposes.
The CGSR provides users with a coordinated approach to conduct research, working closely with other WFBCCC Shared Resources, including:
- Tumor Tissue and Pathology Shared Resource
- Proteomics and Metabolomics Shared Resource
- Biostatistics Shared Resource
- Bioinformatics Shared Resource
The Mission of the CGSR is to provide technical and analytical expertise in genomics research to facilitate high-impact translational science, basic research and clinical cancer genomics.
We provide faculty with comprehensive and cost-competitive genetic analyses focused on:
- Next-generation sequencing for basic and translational cancer research
- Custom library production from bulk tissues and single cells
- RNA and DNA isolation from challenging biological samples
Song Q, Hawkins GA, Wudel L, Levine EA, Watab K, Sun P, Liu L, Miller LD, Kucera G, Topaloglu U, Zhang W, et al.. Dissecting intratumoral myeloid cell plasticity by single cell RNA-seq. Cancer Med. 2019;8(6): 3072-3085. PMC6558497.
Pardee TS, Anderson RG, Howard DS, Isom S, Ghiraldeli LP, Miller LD, Chou JA, Hurd D, Zhang W, Ellis LR, Powell BL, et al.. A phase I study of CPI-613 in combination with high dose cytarabine and mitoxantrone for relapsed or refractory acute myeloid leukemia. Clin Cancer Res. 2018;24(9): 2060-2073. PMC5932089.
Song Q, Hawkins G, Wudel L, Chou PC, Forbes E, Pullikuth A, Liu L, Jin G, Craddock L, Topaloglu U, Kucera G, O’Neill S, Levine E, Sun P, Watabe K, Lu Y, Alexander-Miller MA, Pasche B, Miller LD, Zhang W. Dissecting intratumoral cell-cell interactions in myeloid reprogramming by single cell RNA-seq. Cancer Med. 2019 Jun;8(6):3072-3085. PMC6558497.
Salvador Moreno N, Liu J, Haas KM, Parker LL, Chakraborty C, Kron SJ, Hodges K, Miller LD, Langefeld C, Robinson PJ, Lelièvre SA, Vidi PA. The nuclear structural protein NuMA is a negative regulator of 53BP1 in DNA double-strand break repair. Nucleic Acids Res. 2019 Feb 28. pii: gkz138. doi: 10.1093/nar/gkz138. PMC6451129.
Dohm A, Su J, McTyre ER, Taylor JM, Miller LD, Petty WJ, Xing F, Lo HW, Metheny-Barlow LJ, O'Neill S, Bellinger C, Dotson T, Pasche B, Watabe K, Chan MD, Ruiz J. Identification of CD37, cystatin A, and IL-23A gene expression in association with brain metastasis: analysis of a prospective trial. Int J Biol Markers. 2019 Mar;34(1):90-97. doi: 10.1177/1724600818803104. Epub 2019 Mar 10. PMID: 30854931.
Dotson T, Bellinger C, Su J, Hansen K, Parks GE, Cappellari JO, Craddock L, Clark H, Howard C, Petty WJ, Prakash B, Watabe K, Chan M, Hovda J, Miller LD, Ruiz J. Feasibility of lung cancer RNA acquisition from a single transbronchial or transthoracic needle pass (FASTT trial). Lung Cancer. 2019 Jan;127:6-11. doi: 10.1016/j.lungcan.2018.11.023. PMID: 30642553
Andrews RN, Dugan G, Peiffer AM, Hawkins GA, Hanbury DB, Bourland JD, Hampson RE, Deadwyler SA, Cline JM. White matter is the predilection site of late-delayed radiation-induced brain injury in nonhuman primates. Radiat. Res. 2019 Mar;191(3):217-231. PMC6422025.
Michalson KT, Macintyre AN, Sempowski GD, Bourland JD, Howard TD, Hawkins GA, Dugan GO, Cline JM, Register TC. Monocyte Polarization is Altered by Total Body Irradiation in Male Rhesus Macaques: Implications for Delayed Effects of Acute Radiation Exposure. Radiat. Res. 2019 Aug;192(2):121-134. PMC6698159.
Soike MH, McTyre ER, Shah N, Puchalski RB, Holmes JA, Paulsson AK, Miller LD, Cramer CK, Lesser GJ, Strowd RE, Hinson WH, Mott RT, Johnson AJ, Lo HW, Laxton AW, Tatter SB, Debinski W, Chan MD. Glioblastoma radiomics: can genomic and molecular characteristics correlate with imaging response patterns? Neuroradiology. 2018 Aug 10. doi: 10.1007/s00234-018-2060-y.
Chmielewski JP, Bowlby SC, Wheeler FB, Shi L, Sui G, Davis AL, Howard TD, D'Agostino RB Jr, Miller LD, Sirintrapun SJ, Cramer SD, Kridel SJ. CD38 Inhibits Prostate Cancer Metabolism and Proliferation by Reducing Cellular NAD(+) Pools. Mol Cancer Res. 2018 Aug 3. doi: 10.1158/1541-7786
Panigrahi GK, Ramteke A, Birks D, Abouzeid Ali HE, Venkataraman S, Agarwal C, Vibhakar R, Miller LD, Agarwal R, Abd Elmageed ZY, Deep G. Exosomal microRNA profiling to identify hypoxia-related biomarkers in prostate cancer. Oncotarget. 2018 Feb 17;9(17):13894-13910. doi: 10.18632/oncotarget.24532. eCollection 2018 Mar 2. PMC5862624.
Pardee TS, Anderson RG, Pladna KM, Isom S, Ghiraldeli LP, Miller LD, Chou JW, Jin G, Zhang W, Ellis LR, Berenzon D, Howard DS, Hurd DD, Manuel M, Dralle S, Lyerly S, Powell BL. A Phase I Study of CPI-613 in Combination with High-Dose Cytarabine and Mitoxantrone for Relapsed or Refractory Acute Myeloid Leukemia. Clin Cancer Res. 2018 May 1;24(9):2060-2073. doi: 10.1158/1078-0432. PMC5932089.
Alistar A, Morris BB, Desnoyer R, Klepin HD, Hosseinzadeh K, Clark C, Cameron A, Leyendecker J, D'Agostino R Jr, Topaloglu U, Boteju LW, Boteju AR, Shorr R, Zachar Z, Bingham PM, Ahmed T, Crane S, Shah R, Migliano JJ, Pardee TS, Miller L, Hawkins G, Jin G, Zhang W, Pasche B. Safety and tolerability of the first-in-class agent CPI-613 in combination with modified FOLFIRINOX in patients with metastatic pancreatic cancer: a single-centre, open-label, dose-escalation, phase 1 trial. Lancet Oncol. 2017 Jun;18(6):770-778. doi: 10.1016/S1470-2045(17)30314-5. PMC5635818.
Xing F, Liu Y, Wu SY, Wu K, Sharma S, Mo YY, Feng J, Sanders S, Jin G, Singh R, Vidi PA, Tyagi A, Chan MD, Ruiz J, Debinski W, Pasche BC, Lo HW, Metheny-Barlow LJ, D'Agostino RB Jr, Watabe K. Loss of XIST in Breast Cancer Activates MSN-c-Met and Reprograms Microglia via Exosomal miRNA to Promote Brain Metastasis. Cancer Res. 2018 Aug 1;78(15):4316-4330. doi: 10.1158/0008-5472.CAN-18-1102. PMC6072593.
Nickkholgh B, Sivanandane S, Rothberg MB, Fang X, Li K, Chou JW, Hawkins GA, Balaji KC. Beta-catenin represses protein kinase D1 gene expression by non-canonical pathway through MYC/MAX transcription complex in prostate cancer. Oncotarget 2017 8:78811-78824. PMC5668000.